MedTrace Logo

Use of Tranexamic Acid After Vaginal Delivery with Episiotomy a RCT Placebo Control Trail

NCT05448456 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-12-05

No results posted yet for this study

Summary

The objective of this study is to assess the effect of TA treatment on decline in Hb levels following vaginal delivery with an episiotomy, compared to a control group not receiving TA.

Conditions

  • Episiotomy Wound
  • Anemia
  • Early Postpartum Hemorrhage
  • Hemoglobin

Interventions

DRUG

Tranexamic acid

1 gram of tranexamic acid in 100 ml of 0.9% normal saline

DRUG

Placebo

100 ml of 0.9% normal saline

Sponsors & Collaborators

  • Assuta Ashdod Hospital

    lead OTHER

Principal Investigators

  • Atara De Porto Amrany, MD · Samson Assuta Ashdod University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-25
Primary Completion
2023-08-22
Completion
2024-09-01

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05448456 on ClinicalTrials.gov